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Iron oxide nanoparticles have strong potential as MRI 
contrast agents, though their popularity has plummeted 
in recent years, due to low efficacy and safety concerns, 
including haemagglutination. There is therefore a real need 
for new contrast agents with excellent MRI capabilities and 
biocompatibility. This work describes the preparation of 
heparin-stabilised iron oxide nanoparticles with extremely 
strong MRI contrast behaviour at clinically-relevant and low 
field strengths which outperform current clinical standards. 
The stable colloidal nanoparticles further efficiently prevent 
protein-adsorption triggered thrombosis and show strong 
potential as the next generation of MRI contrast agents.
This journal is©The Royal Society of Chemistry 2016 J. Mater. Chem. B, 2016, 4, 3065--3074 | 3065
Cite this: J.Mater. Chem. B, 2016,
4, 3065
Heparin-stabilised iron oxide for MR applications:
a relaxometric study†
Lucy Ternent,a Daniel Alexander Mayoh,b Martin Richard Leesb and
Gemma-Louise Davies*c
Superparamagnetic nanoparticles have strong potential in biomedicine and have seen application as
clinical magnetic resonance imaging (MRI) contrast agents, though their popularity has plummeted in
recent years, due to low eﬃcacy and safety concerns, including haemagglutination. Using an in situ
procedure, we have prepared colloids of magnetite nanoparticles, exploiting the clinically approved
anti-coagulant, heparin, as a templating stabiliser. These colloids, stable over several days, produce
exceptionally strong MRI contrast capabilities particularly at low fields, as demonstrated by relaxometric
investigations using nuclear magnetic resonance dispersion (NMRD) techniques and single field r1 and r2
relaxation measurements. This behaviour is due to interparticle interactions, enhanced by the templating
eﬀect of heparin, resulting in strong magnetic anisotropic behaviour which closely maps particle size.
The nanocomposites have also reliably prevented protein-adsorption triggered thrombosis typical of
non-stabilised nanoparticles, showing great potential for in vivo MRI diagnostics.
Introduction
Magnetic Resonance Imaging (MRI) is an important non-
invasive tool in medical diagnostics.1 Contrast agents (CAs) are
often applied to improve signal contrast and work by decreasing
the T1 or T2 relaxation times of the indigenous water present in
the body through close interactions. Such interactions are
governed by physical parameters, including hydration number (q),
rotational correlation time (tR), water residence lifetime (tm)
and diﬀusional correlation time (tD), amongst others, which
have previously been described in detail using the Solomon,
Bloembergen and Morgan (SBM) theory.2–4 Positive CAs, based
on paramagnetic Gd3+ ions are the clinical standard, providing
hyperintensive areas of signal which are diagnostically useful.1,3
Iron oxide, usually in the form of superparamagnetic magnetite
nanoparticles, is a common negative contrast agent in MR
imaging, producing areas of hypointensive signal.4,5
Magnetite nanoparticles have seen commercial use as MRI
CAs for a number of years, for example, Feridexs and Resovists.
These commercial formulations are stabilised magnetic fluids
composed of aggregates of magnetite nanoparticle cores with
polymer (e.g. dextran) coatings.4,6 In recent years, however their
popularity in the clinic has plummeted, due to low eﬃcacy and
safety concerns. Nevertheless, they remain popular in research,
as they are widely accepted to pose a low cytotoxic risk for
mammalian cell lines and hosts.5,7
The key features of high signal contrast nanoparticulate MRI
CAs include excellent colloidal stability, along with strong
magnetic properties, well-hydrated surfaces and biocompatibility–
physical properties which are strongly linked to nanoparticle size
and architecture of assemblies.4,8 Poor aqueous colloidal stability
inevitably results in agglomeration, an effect known to lead to
rapid clearance from blood circulation and unexpected responses,
including haemagglutination in the body.9 The incorporation of
stabilising agents has therefore been adopted to engender the
appropriate long-term stability required of a medical contrast
agent.10 In situ incorporation of a stabiliser during the preparation
of iron oxide nanoparticles provides one of the best approaches to
long term stability, which can also enhance the magnetic response
of colloidal particles, and hence their MR contrast capabilities.10,11
The use of block copolymers or charged polyelectrolyte species
(e.g. DNA or DNA-mimics, such as poly(sodium-4-styrene)
sulfonate (PSSS)) during the synthesis of magnetite nanoparticles
has been observed to provide stable magnetic fluids with enhanced
magnetic resonance properties.10,12–15
Dispersive nuclear magnetic resonance (NMRD) is a useful
tool in the analysis of the relaxation properties of colloidal
magnetic nanoparticles.8,16 It can provide a quantitative assess-
ment of the potential usefulness of a CA species in the clinical
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MRI frequency range (10–60 MHz). NMRD uses SBM theory to
describe the relaxation rate of a suspending medium and the
effect of a CA on it.17 Specifically, it provides information about
the relaxation behaviour of 1H spins in a system, through the
measurement of water relaxation rate enhancement per mmol
of CA, or spin–lattice relaxivity, r1, defined by eqn (1), as a





where R1sample is the measured relaxation rate of a nanoparticle
suspension (where R1 = 1/T1) and R1water is the measured
relaxation rate of water in the absence of a CA. [CA] represents
the total millimolar concentration of active CA species (in the
case of magnetite nanoparticles, iron).
The choice of stabilising agent is crucial, not only on
influencing the relaxation eﬃciency and subsequent stability
of the magnetic fluid, but also on pharmacokinetics, behaviour
and biocompatibility with human cells and physiology. Surface
coating of nanoparticles with some agents (e.g. polymers, including
polyethylene glycol) has been shown to inhibit opsonisation
and delay phagocytosis by the mononuclear phagocyte system
(MPS), which is beneficial for increasing blood circulation
times.9,18,19 Dextran is a popular stabilising agent; however,
despite being Food and Drug Administration (FDA) approved
and regularly used clinically, it provides poorly defined magnetic
fluids and several contrast agents utilising this polymer have
been withdrawn from the market in recent years (e.g. Sinerems)
due to poor eﬃcacy. There is therefore a real need for new
CA species with excellent MRI contrast capabilities which are
also biocompatible.
Heparin is an FDA approved linear glycosaminoglycan
which is highly charged and is regularly used clinically as an
anticoagulant.20 Its negatively charged backbone (Scheme 1), its
strong biocompatibility, coupled with its ability, when immobilised
onto nanoparticle surfaces, to dramatically reduce the rate of
phagocytic uptake (evading the MPS), reduce opsonisation in
culture and prevent agglomeration due to its strongly hydro-
philic surface, make it an ideal candidate as a magnetic nano-
particle stabilising agent.18 Positively charged stabilised iron oxide
particles, on the other hand, have been shown to have a higher
cytotoxic eﬀect on cells and animal models than negatively
charged analogues.21 Some reports of heparin-stabilised magnetic
nanoparticles have demonstrated their usefulness in the labelling
of human mesenchymal stem cells and cell tracking,22 drug
delivery,23,24 labelling and imaging of pancreatic islets,25 with
some of these demonstrating excellent T2-weighted (in vivo)
MRI of tissues and cells,26–28 indicating that such stabilised
systems are promising as MRI CAs. There have not, however,
been any studies to date which describe in detail the impor-
tance of precise composition of the magnetic fluid (in terms of
molar reactant ratios) on their magnetic resonant properties.
Herein, we aim to produce a family of heparin-stabilised
magnetite nanoparticles, prepared through the variation of
reagent ratios using an in situ approach, and determine their
relaxometric characteristics utilising variable field relaxation
(NMRD) and single field relaxation studies. The particles will
also be assessed for their anti-thrombotic/haemagglutination
behaviour (if any).
Results and discussion
Physical and structural behaviour
Heparin-stabilised Fe3O4 nanoparticles were prepared in a one
pot in situ synthesis, by co-precipitating FeII and FeIII salts in a
1 : 2 molar ratio in the presence of heparin (Scheme 1) at varying
molar ratios of iron : heparin, as detailed in Table 1 and the
Experimental section. Using this approach, the polyelectrolyte
species behaves as a templating agent (vide infra), producing
magnetic fluids of stabilised magnetite nanoparticles.
Phase identity was confirmed using X-ray diﬀraction (XRD);
patterns were in good agreement with the reported structure for
inverse spinel cubic magnetite (Fig. 1).29 Raman spectra (Fig. 2)
recorded for all composites display peaks at 670 and 190 cm1,
which are representative of the A1g and T2g modes of magnetite
respectively; broad peaks centred at 340 and 500 cm1 represent
Eg and T2g modes of magnetite. These appear with relatively high
intensities due to an overlap with T1 and E modes of maghemite
impurities in the sample.30–32 The presence of maghemite in the
samples is likely to be due to oxidation of the sample during
measurement due to heating from the high intensity of the laser.
Infrared (IR) spectroscopy (Fig. 3) shows non-stabilised
Fe3O4 nanoparticles with bands between 3600–3100 cm
1
representing OH stretching vibrations from surface hydroxyl
groups and physisorbed water groups, in-plane and out-of-plane
OH stretching between 1110–1090 cm1 and 1070–1030 cm1
and the stretch between 670–500 cm1 representing Fe-O
(bands labelled and highlighted in yellow, Fig. 3).14 The IR
spectrum of heparin shows bands representing asymmetric and
symmetric COO stretching (1660–1530 and 1440–1400 cm1),
asymmetric and symmetric OQSQO stretching (1380–1350
and 1310–1190 cm1), symmetric and asymmetric C–O–C
stretching (1170–1130 and 1050–950 cm1), asymmetric and
symmetric S–O–C stretching (910–880 and 870–840 cm1), C–H
bending (1490–1450 cm1) and N–H wagging (820–800 cm1)
vibrations (bands labelled and highlighted in grey, Fig. 3).
Stretches representing Fe3O4 and heparin can be observed in
the heparin-stabilised samples 1–5, these correspond well with the
non-stabilised sample and heparin reagent spectra (as highlighted
in Fig. 3). There is some shifting (o100 cm1 shifts, highlighted
with striped grey bars in Fig. 3) in the frequency of stretches
Scheme 1 Representation of the in situ preparation of heparin-stabilised
Fe3O4 nanoparticles.





























































































This journal is©The Royal Society of Chemistry 2016 J. Mater. Chem. B, 2016, 4, 3065--3074 | 3067
representing sulfonate groups (OQSQO and S–O–C), which is due
to the interaction of these groups with the Fe3O4 particle surfaces.
33
Magnetometry was performed on all solid samples prepared
(Fig. 4). Non-stabilised Fe3O4 nanoparticles possessed a magnetic
saturation value at 20 kOe (Ms) of 72.1  0.1 emu g1. This is
slightly lower than reported for bulk magnetite (92 emu g1),
however the value obtained is comparable to reported values
for magnetite formed in this manner.34–36 Heparin-stabilised
samples had Ms values varying between 56–70 emu g
1
(Ms measured per total mass of sample; Table 1), with values
decreasing with increasing heparin content in samples, as expected
Table 1 Reagent ratios and sample characteristics of non-stabilised and heparin-stabilised Fe3O4 nanoparticles
[Fe]a (mM) [Heparin]a (mM)
[Fe] : [Heparin] ratioa
(Bmonomer ratio) dhyd
b (nm) [PDI] z-pot.b (mV) dcore
c (nm) Ms
d (emu g1)
Fe3O4 — — — — — 8.9  2.5 72.1  0.1
1 50 0.008 6250 (595) 43.5  0.3 [0.158] 26.5  0.8 9.0  1.3 69.2  0.1
2 50 0.01 5000 (476) 60.9  0.6 [0.131] 17.1  0.4 8.3  1.3 69.3  0.1
3 50 0.02 2500 (238) 57.2  0.3 [0.123] 31.2  0.4 8.9  1.2 67.3  0.1
4 30 0.02 1500 (143) 88.3  0.6 [0.197] 33.2  0.1 7.7  1.0 66.5  0.1
5 30 0.30 100 (9.5) 103.2  0.3 [0.162] 36.8  0.8 6.7  1.1 56.4  0.1
a Total initial concentration of reagents. b Hydrodynamic diameter (dhyd), zeta potential (z-pot.) and polydispersity index (PDI) calculated from
dynamic light scattering. c dcore average particle size calculated from 4100 particles as analysed from transmission electron microscope images.
d Magnetic saturation at 20 kOe (Ms), measured per total mass of sample.
Fig. 1 XRD patterns of non-stabilised Fe3O4 and heparin-stabilised
Fe3O4 nanoparticles 1–5, prepared according to Table 1. Dashed lines
represent expected peak positions for cubic magnetite according to the
JCPDS database.
Fig. 2 Raman spectra of heparin-stabilised Fe3O4 nanoparticles 1–5,
prepared according to Table 1.
Fig. 3 IR spectra of non-stabilised Fe3O4 nanoparticles, heparin and heparin-
stabilised Fe3O4 nanoparticles 1–5, prepared according to Table 1, as labelled
(top). Black squares are zoomed in (bottom, as labelled) with bands labelled
and highlighted: yellow for stretches associated with Fe3O4, grey for those
associated with heparin, with shifted stretches due to association of heparin
with particles highlighted by striped grey bars and red text.
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due to the mass contribution of the non-magnetic polymer
component. All samples demonstrated typical superparamag-
netic characteristics, indicating that the presence of heparin
during the co-precipitation procedure did not negatively affect
the resulting magnetite nanoparticles.
The stable aqueous colloids (final washings – see Experimental
section) were characterised by transmission electron microscopy
(TEM, Table 1 and Fig. 5) and dynamic light scattering (DLS,
Table 1 and Fig. 6) and NMRD analysis (Fig. 7). Fig. 5 shows the
presence of discrete nanoparticles which exist as aggregates in the
absence of a magnetic field. The primary particle size (dcore)
increases with increasing metal to polyelectrolyte ratio (Table 1),
indicating increased primary particle growth due to the presence
of increased amounts of iron.13
Nanoparticle samples which were dried (on TEM grids) in
the presence of an external permanent parallel magnetic field
demonstrated strong parallel 1-dimensional linear alignment
along the field axis (Fig. 5). This behaviour is not unexpected,
as in addition to their role as stabilising agents, helping to
overcome particle aggregation in suspension, polyelectrolytes
are well-known to behave as templating species. The negatively
Fig. 4 Magnetisation (mass susceptibility) versus field profiles of non-
stabilised Fe3O4 and heparin-stabilised Fe3O4 nanoparticles 1–5, prepared
according to Table 1.
Fig. 5 Transmission electron microscope (TEM) images of non-stabilised Fe3O4 and heparin-stabilised Fe3O4 nanoparticles 1–5, labelled as prepared
according to Table 1. Top row: images taken in the absence of a magnetic field at high magnification. Middle row: images taken in the absence of a
magnetic field at low magnification. Bottom row: images taken in the presence of a parallel permanent magnetic field at low magnification. Schematics
represent the behaviour of stabilised Fe3O4 particles in the absence and presence of a parallel magnetic field.
Fig. 6 (a) Hydrodynamic diameters (dhyd) of heparin-stabilised Fe3O4
nanoparticles 1–5, prepared according to Table 1, recorded over several
days showing negligible changes in size; (b) photographs of samples over
several days illustrating precipitation of non-stabilised Fe3O4 and stability
of heparin-stabilised samples 1–5, as labelled.
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charged backbone of heparin provides sites for seeding and
formation of Fe3O4 nanoparticles. During synthesis, Fe
II/III ions
associate with the negative sulfonate groups through electrostatic
interactions.10,15 Co-precipitation then results in the formation
of magnetite nanoparticles which remain strongly associated
with these negative sites, enhancing their colloidal stability. In
the presence of an external magnetic field, the dipoles of the
superparamagnetic nanoparticles align in the direction of the
applied magnetic field. The presence of the polyelectrolyte
directs their self-assembly into 1-D linear arrays,11,15,37 structures
which are reversible upon removal of the magnetic field, due to
their superparamagnetic nature. Non-stabilised Fe3O4 particles
showed significant aggregation in comparison. Application of a
magnetic field resulted in some alignment, but arrays were non-
linear and disorganised aggregation was observed.
Average hydrodynamic diameters (dhyd) as measured by DLS
(Table 1) were in the range 40–105 nm, values significantly
higher than those measured by TEM, due to hydrogen bonding
and van der Waals interactions present as the particles, associated
with long polymer chains, move according to Brownian motion
in the aqueous phase. Particle dhyd generally increased with
increasing amounts of polymer, as expected, due to increased
inter-particle interactions between neighbouring polyelectro-
lyte chains which are expected to remain flexible in suspension
and likely to interpenetrate. Polydispersity indices of o0.2 for
all samples indicated the strong colloidal stability of these
fluids (note that non-stabilised samples did not provide stable
suspensions, therefore their dhyd characterisation details are
omitted from Table 1).
To confirm their long-term aqueous stability, sample hydro-
dynamic diameters (dhyd) were measured daily over several
days without disturbance; dhyd showed no significant changes
over a 16 day period (Fig. 6). Fig. 6b also clearly shows
the absence of precipitation in heparin-stabilised samples,
whereas non-stabilised Fe3O4 particles quickly precipitate out
of suspension.
Zeta potential measurements (z-potential, Table 1) provide
an indication of the surface charge of a species. The z-potential
of the reagents prior to reaction are shown in Table S1 (ESI†).
These demonstrate that, uponmixing and prior to co-precipitation,
the positively charged FeII/III solutions and negatively charged
heparin solutions are not simply mean values of the unmixed
solutions. Their more positive values (than native heparin
alone) indicate that iron ions are likely to be associating with
the negatively charged backbone of the polyelectrolyte, as
previously described. The prepared nanoparticle samples are
strongly negatively charged (varying between 37 to 17 mV,
Table 1), due to the negative surface charge of the particle
hydroxyl surface groups and the presence of the negative
stabiliser in samples 1–5.
Relaxometric behaviour
NMRD has been widely used to demonstrate the eﬃcacy of
colloidal suspensions of magnetic nanoparticles asMRI CAs.8,13–17,38
The longitudinal proton nuclear relaxation rate of a colloidal system
is influenced by the physical properties of a particle and its
interaction with its surroundings (altering its rotational or transla-
tional molecular motions). It can therefore also be used to provide
insights into the dynamic environment of hydrated nanostruc-
tured materials.13 NMRD profiles (Fig. 7) for the heparin-stabilised
Fe3O4 samples, prepared according to Table 1, show typical
superparamagnetic behaviour, corresponding well to theory.39
Profiles consist of a low field plateau, a mid-field peak in
relaxation (vmax), and a decrease in relaxivity (r1) at increasing
field strengths. Relaxation behaviour in the high frequency
region is based on Curie relaxation, a phenomenon caused by
the appearance of a local magnetic field resulting from the
application of an external magnetic field to paramagnetic
ions.39 The relaxation in this region is determined primarily
by the strength of moments and diffusional correlation times
and tend to correlate with the dcore size,
13 which is similar for
all samples, therefore the profiles converge at 420 MHz.
Low frequency behaviour (often referred to as the low field
dispersion) is driven by random fluctuations of the nanoparticle
moments (Ne´el relaxation)8 and is of critical importance to the
shape of an NMRD profile.39,40 Herein, the low field relaxation
plateau is observed to increase with increasing core particle size
(and Ms) and can be explained by the particles’ anisotropy
energy. The high values observed are indicative of the presence
of nanoparticle assemblies, with magnetic anisotropy arising
from strong dipole interactions due to their arrangement along
the templating backbone of the polyelectrolyte stabiliser. This
trend correlates with the increased density of particle nucleation
along the polyelectrolyte backbone (dict. erat), with r1 and
vmax increasing (and vmax shifting to lower frequencies) with
increasing Fe:Hep ratio, where more iron is available to participate
in interparticle interactions.14 This agrees with previously observed
behaviour for similar systems of colloidal g-Fe2O3 indicating
that low field relaxation increases with increasing particle size
are limited by Ms.
38 The theory is strictly limited to sub-20 nm
particles with uniaxial magnetocrystalline anisotropy and there-
fore it should be noted that this is not an infinitely expansive
Fig. 7 1H NMRD profiles for heparin-stabilised Fe3O4 nanoparticles 1–5,
prepared according to Table 1. The r1 values have been calculated in terms
of [Fe] content of the samples. Profiles have been measured at two
different temperatures, representative of room temperature (27 1C) and
body temperature (37 1C).
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trend, as increasing cluster sizes have also been observed to
result in decreased r1 values; with relaxivity limited by the
surface area to volume ratio of clusters, where central iron
species contribute less to the relaxation behaviour.8 In the case
of the samples analysed herein, particles remain small enough
that this does not become an issue and stay within the domain
of the theory. The observed parallel alignment of particles in
the presence of an external magnetic field (Fig. 5) provides
further corroboration of this, as high aspect ratio magnetic
materials are known to possess larger dipole moments, providing
the opportunity for strong dipole interactions and hence mag-
netic anisotropy.41
Relaxation behaviour for all samples was reduced at
higher temperatures (37 1C), an eﬀect which is particularly
amplified at low field strengths (Fig. 7). This is a well-known
phenomenon15,42 which is associated with the altered beha-
viour of water at higher temperatures and its resulting eﬀect on
tR, tm and tD.
43,44 It should be noted that non-stabilised Fe3O4
provides unreliable relaxation data due to its lack of aqueous
colloidal stability and heparin does not contribute directly to
relaxation behaviour due to its non-paramagnetic nature (as
previously observed in magnetometry measurements).
The strong hydration of hydrophilic polyelectrolyte species
may also result in changes in critical dynamic processes such as
tR, tm and tD in composites formulated from them. Alteration
of these correlation times is associated with an enhancement of
the interaction of water with a CA. Such behaviour has been
demonstrated to boost the r1 relaxation behaviour of similar
systems13,45 and systems designed to geometrically confine
water.46–48 An inverse correlation is observed between the
hydrodynamic diameter (dhyd) and low field relaxivity of all
the stabilised samples herein (Fig. 8). The higher surface area
to volume ratio of the smaller species provides a higher surface
area available for surface-water interactions. This correlates well
with previous reports which demonstrated that microscopic
interactions between water and such nanocomposites are largely
governed by hydrodynamic size.13,45
Transverse relaxation data (r2 relaxivity) was collected at a
single field strength (13.2 MHz or 0.47 T) at room temperature
(Table 2) to provide further insight into the potential of these
species as negative contrast agents. Since this mechanism of
relaxation is governed by the dephasing of spins and is not
proportional to the Larmor frequency, acquisition of data at
multiple field strengths would not provide any further insights
into particle behaviour. r2 relaxivity is strong for all samples
and follows a general inverse correlation with sample hydro-
dynamic diameter, similar to that observed for r1 at low fields
(in Fig. 8). This relationship follows the well-known Koenig–Keller
model of T2 relaxation, which shows an inverse relationship
between relaxation and particle diameter, as this mechanism
is dominated by diffusive outer sphere interactions.4,49 The high
r2/r1 ratios observed for all samples demonstrate their strong
potential as negative contrast agents.
Thrombotic eﬀect
Heparin is a popular clinically-used anti-coagulant whose
activity results from a conformational change upon binding
to the enzyme inhibitor antithrombin III, which leads to
deactivation of thrombin and other proteases (e.g. factor Xa)
involved in blood clotting. As a known anti-coagulant, heparin
(in suﬃcient quantity) may extend the plasma recalcification
time (PRT) of blood.18 In order to determine whether the
heparin-stabilised nanoparticles prepared herein aﬀect blood
thrombosis, particles were tested using a PRT assay (see Experi-
mental section). Fig. 9 shows the time taken for a firm blood
clot to form in the presence of control (water only), heparin,
non-stabilised iron oxide nanoparticles and heparin-stabilised
iron oxide nanoparticles. High concentrations of heparin
(0.5 mg ml1 to 1 mg ml1) eﬃciently prevented the formation
of a blood clot (436 h, not included in Fig. 9 for clarity); lower
concentrations of heparin (5 mg ml1), however, led to PRT
similar to control samples (296  24 s). Non-stabilised nano-
particles (50 mg ml1) demonstrated slightly shortened coagula-
tion times (266  1 s, denoted by black stars), indicating that
non-stabilised iron oxide nanoparticles increase the thrombotic
eﬀect, due to the adsorption of blood or blood components
onto nanoparticle surfaces, speeding up the blood clotting
process.18 Heparin-stabilised nanoparticles (samples 1–5) on
the other hand, showed PRTs which were generally within
error of the control samples (288–351 s). This is reasonable,
due to the low concentrations of heparin used to stabilise the
Fig. 8 Low frequency relaxivity (r1 at 0.01 MHz at 27 1C (filled symbols)
and 37 1C (open symbols)) of heparin-stabilised Fe3O4 nanoparticles 1–5,
plotted as a function of hydrodynamic diameter (dhyd). Dotted lines
represent a linear fit of data collected at 27 1C (black) and 37 1C (red).
Table 2 Relaxivity values of heparin-stabilised samples 1–5, prepared
according to Table 1
Sample r1
a (mM1 s1) r2
a (mM1 s1) r2/r1 ratio
1 42.9 181.5 4.2
2 34.0 201.6 5.9
3 32.3 172.2 5.3
4 37.2 264.9 7.1
5 23.1 139.9 6.1
a Measured at 25 1C at 13.2 MHz.
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nanoparticles not being high enough to lengthen the PRT, but
providing stable colloids with coatings which are capable
of preventing the adsorption of blood components which lead
to accelerated PRT observed in the absence of stabiliser.
Though there are a series of factors which can affect the anti-
thrombotic efficiency of heparin, molecular weight is thought
to be amongst the most important. High molecular weight
(410 kDa) species, similar to those used herein, have low
activity, due to differences in pharmacokinetic behaviour.50
Sample 2 showed slightly longer PRT than control samples
(351  27 s, denoted by black stars), demonstrating that this
sample has slightly increased anti-coagulation activity, which
may be useful for in vivo applications.18 Similar behaviour was
observed for all samples analysed in the presence of an external
magnetic field. Non-stabilised Fe3O4 again shortened coagula-
tion times, whereas sample 2 slightly lengthened coagulation
times compared to the control, as before (denoted by red stars).
Importantly, PRTs measured in the presence of a magnetic field
were within error of values measured in the absence of a magnetic
field for all samples, indicating that magnetically-induced
alignment (observed in Fig. 5) does not induce undesirable
thrombotic effects.
Conclusions
It has long been acknowledged that careful control during the
preparation and assembly of nanomaterials can lead to
improved properties.8,47 In particular, engineering of iron oxide
nanostructured materials can boost their magnetic relaxation
behaviour and hence MR imaging capabilities. Magnetic inter-
actions between magnetic nanoparticles and water molecules is
of critical importance to strong relaxation and is therefore key
to the development of the next generation of MRI CAs. NMRD is
a useful technique which can provide insights into such inter-
actions. Its sensitivity to the solvation of nanostructures,
the dynamic environment of nanoparticle assemblies and
their interparticle interactions means that NMRD can provide
unrivalled information.
Herein, we have demonstrated that careful control over
the preparation of magnetite nanoparticles in the presence of
a clinically approved polyelectrolyte species (heparin) can pro-
duce stable magnetic fluids with extremely high magnetic
relaxation properties, particularly at low field strengths. When
exploited as a stabiliser during the preparation of iron oxide
nanoparticles, heparin behaves as a templating agent, whose
negatively charged backbone provides sites for nanoparticles to
seed and produce stable colloids. This results in nanoparticle
assemblies with strong magnetic anisotropy arising from inter-
particle interactions, in turn leading to the observed boosts in
low frequency relaxivity of stabilised samples, a trend which is
mapped closely to the core size of the nanoparticles (and their
saturation magnetisation). Due to the strong hydration of the
iron oxide colloids, resulting from the hydrophilic stabilising
species, an inverse correlation between hydrodynamic diameter
and low field relaxivity is observed, with r1 being limited by the
hydrodynamic surface area.
Due to the range of field strengths over which data is collected
in NMRD studies, it is of direct relevance for biomedical applica-
tions. When compared with some commercial iron oxide contrast
agents and similarly-produced stabilised ferrites (prepared using
non-clinically approved stabilisers), our magnetic fluids (the range
of values achieved by samples 1–5 has been included in Table 3)
have superior r1 and r2 relaxivities and r2/r1 ratios higher than
Fig. 9 Bar chart representation of the eﬀect on time to form a firm blood
clot of control (water only), non-stabilised Fe3O4 nanoparticles, heparin-
stabilised Fe3O4 nanoparticle samples 1–5, prepared according to Table 1
and a low concentration heparin solution; data collected in the absence
and presence of a magnetic field (+mag.) as labelled. Results are repre-
sented as mean values based upon a minimum of 3 repetitions. Stars
indicate statistically significant results (Po 0.05) compared to the control
in the absence (black lines and stars) and presence (red lines and stars) of
an external magnetic field.
Table 3 Relaxivity values (r1 and r2) of commercial and literature examples of stabilised iron oxide nanoparticle samples compared to the heparin-
stabilised Fe3O4 nanoparticle samples 1–5 prepared herein
Sample r1 (mM
1 s1) at 20 MHz r2 (mM
1 s1) at 20 MHz r2/r1 ratio at 20 MHz
Feridexs51 23.7a 107.0a 4.5
Resovists52 25.4a 151.0a 6.0
Sinerems51 22.7a 53.1a 2.3
PSSS-stabilised Fe3O4
15 22.5a,b 132.4a,b 5.9b
PSSS-stabilised CoFe2O4
13 31.1c — —
Heparin-stabilised Fe3O4
e 22.9–33.7a,f, 23.9–34.8d,f 139.9–264.9c,g 4.2–7.1c,g
a Measured at 37 1C. b Measured at 9 MHz. c Measured at 25 1C. d Measured at 27 1C. e Relaxivity value ranges for samples 1–5. f Measured by
NMRD, extracted from Fig. 7. g Measured at 13.2 MHz (Table 2).
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those previously reported (Table 3), indicating that these species
would be useful as negative contrast agents. Growing interest in
ultra-low-field imaging (ULF-MRI) due to its lower costs,
increased safety and mobility may lead to CAs which have high
efficacy in these low fields becoming the next market-leaders.
The alignment of magnetite nanoparticles (aided by the
templating stabiliser heparin) into 1-D linear arrays presents
an interesting snapshot into particle behaviour in the presence
of an applied magnetic field (such as that applied during MRI
and NMRD measurements). Such magnetic particle alignment
is not a new concept, however this structural behaviour corro-
borates NMRD evidence herein of strong magnetic anisotropic
behaviour resulting from interparticle interactions. Further, large
aspect ratio structures have been reported to provide advantages
in nanosensor devices, flow cytometry and cellular payload delivery,
where the 1-D morphology of nanocomposites facilitates easy
passage through the circulatory system.15,53–57 Sub-200 nm
particles are generally believed to be able to avoid uptake by
the reticuloendothelial system (RES), with the addition of
hydrophilic polymer coatings providing a ‘masking’ effect,
aiding this evasion.18,19 Large aspect ratio 1-D nanostructures
exhibit minimal macrophagic uptake, particularly under fluid
flow conditions similar to those expected in the human circulatory
system.58,59 As such, the 1-D nanocomposites formed in the
presence of a magnetic field reported herein are not anticipated
to accelerate recognition and uptake by the RES.
The prepared nanoparticles additionally have minimal eﬀect
on the coagulation behaviour of blood samples (whether in
the absence or presence of an externally applied permanent
magnetic field), serving to prevent unwanted acceleration of
blood clotting which is triggered by the presence of non-
stabilised Fe3O4 nanoparticles.
18 This makes them promising
as medical imaging agents, potentially circumventing previously
reported issues with iron oxide-based MRI contrast agents.
Collectively, the results presented herein indicate that our
nanocomposites, fabricated from clinically-approved species,
possess strong potential as the next generation of MRI contrast
agents, particularly at low frequencies.
Experimental
All chemicals were used as supplied. FeCl24H2O, FeCl36H2O,
CaCl2, NaCl and ammonium hydroxide (28 v/v%) were purchased
from Sigma-Aldrich. Heparin sodium salt (8–25 kDa) and blood
collection tubes with clot activator were purchased from VWR
UK and used as received. Fresh sheep’s blood in Alsever’s
was purchased from TCS Biosciences and used as received.
Ultrapure water was collected from a Millipore MilliQ system
operated at 18.2 MO.
Non-stabilised Fe3O4 nanoparticles were prepared using
a co-precipitation technique. FeCl24H2O (2.48 g, 12 mmol)
and FeCl36H2O (6.5 g, 24 mmol) were dissolved in 25 mL
deoxygenated water (prepared by bubbling N2 for B20 min);
this solution was added dropwise to a deoxygenated 0.5 M
NaOH solution and stirred at 40 1C for 1 h. The resulting brown
precipitate was washed with Millipore water using centrifuga-
tion until the pH was neutral (5  25 ml). The precipitate was
dried under vacuum and analysed.
Heparin stabilised Fe3O4 nanoparticles were prepared using an
in situ co-precipitation technique.13 FeCl24H2O (0.4 g, 2 mmol)
and FeCl36H2O (1.08 g, 4 mmol) were dissolved in 100 mL
deoxygenated water. Aliquots of this solution were added to
aqueous deoxygenated heparin solutions of known concentra-
tions (Table 1, 10 mL water). Ammonium hydroxide solution
was added until the pH reached 11. The solution was reacted at
40 1C with stirring for 2 h. The resulting brown precipitate was
washed with Millipore water using centrifugation until the
pH was neutral (5  25 ml). The final washings were retained
for NMRD analysis, as these were stable suspensions. The
precipitate was dried under vacuum for analysis.
TEM images were obtained on a JEOL 2000fx microscope,
200 kV, LaB6 instrument operated with a beam current of
B115 mA; images were captured using a Gatan Orius 11 mega-
pixel camera. Samples were prepared by deposition and drying of
nanoparticle samples (10 mL of stock stable magnetic fluid
suspensions) onto lacey carbon or formvar-coated 300-mesh
copper TEM grids (Agar Scientific). Diameters were measured
using ImageJ version 1.48a; average values were calculated by
counting a minimum of 100 particles. Magnetically aligned
samples were dried in the presence of a parallel permanent
magnetic field (B0.1 T).
Hydrodynamic particle size and zeta potential measure-
ments were determined by Dynamic Light Scattering (DLS)
using a Malvern Zetasizer Nano ZS instrument. A 4 mW
He–Ne 633 nm laser module was used and scattered light was
measured at 1731 (back scattering). The attenuator and position
was selected automatically by the instrument and particle sizes
reported as the average of 5 measurements. The long-term
stability study was carried out by placing 1 mL of aqueous
colloid (as prepared according to Table 1) into a 4.5 mL cuvette
and measuring hydrodynamic diameter every day for several
days with minimal disturbance. Samples were stored sealed at
room temperature between measurements.
Fourier transform infrared (FTIR) spectra were acquired using
a Bruker Vector 22 FTIR spectrometer with a Golden Gate
diamond attenuated total reflection cell. A total of 64 scans were
collected on solid samples after drying. X-ray powder diﬀraction
was performed using a Bruker D5000 diﬀractometer with a
Cu Ka lamp. Raman spectra were collected using an inVia
Raman microscope with a 785 nm solid state diode laser and
50 objective lens. Magnetisation measurements were carried
out between 20 and 20 kOe in an Oxford Instruments vibrating
sample magnetometer (VSM) or a Quantum Design Magnetic
Property Measurement System (MPMS) superconducting quantum
interference device magnetometer. Measurements (emu g1)
are based on the total mass of the sample measured; in the case
of heparin-stabilised Fe3O4, this includes the mass contribu-
tion of non-magnetic heparin.
Measurement of 1H NMRD profiles was performed on
a Stelar Spinmaster FFC2000 1 T instrument in the range of
0.01–40 MHz Larmor frequency at two different temperatures
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(27 1C and 37 1C). The temperature was controlled using a Stelar
VTC-91 airflow heater, equipped with a copper-constantan
thermocouple; the temperature calibration in the probe head
was carried out using a Delta OHM digital thermometer, with an
absolute accuracy of 0.5 1C. Fast field cycling (FFC) relaxometry
was used to determine the longitudinal relaxation decay over a
range of relaxation fields (0.01–40 MHz). A set of 24 relaxation
interval values (tau) allowed description of the spin–lattice decay
curves for each relaxation field. A standard fitting algorithm
(mono-exponential relaxation decay curve) allowed the evalua-
tion of the relative longitudinal relaxation rate (R1 = 1/T1), which
was converted to relaxivity using eqn (1).
Measurement of r1 and r2 values at a fixed field strength
were carried out using a XiGo Nanotool with a resonant
frequency of 13.2 MHz operated at room temperature. For the
measurement of T1, the standard inversion-recovery method
was employed with a typical 901 pulse calibration of 250 ms with
4 scans per experiment; for T2, the Carr–Purcell–Meiboom–
Gill (CPMG) method was used with 4 scans per experiment.
A minimum of 3 different concentrations of stable nanoparticle
samples were prepared and relaxation time measured for each
sample. r1 and r2 relaxivity values were calculated from curves
plotted of R1 (1/T1, s
1) or R2 (1/T2, s
1) vs. [Fe] concentration
(mM, as measured by ICP-MS) and analysis of the slope of the
line of best fit for each sample, with error measured from a
minimum of 3 repetitions for each concentration point.
An Agilent 7500cx Inductively Coupled Plasma Mass Spectro-
meter (ICP-MS) was used to determine iron concentrations of
stable aqueous suspensions of particles treated by hot nitric
acid digestion. Concentrations as measured by this technique
were used to normalise all relaxation data according to eqn (1).
Plasma recalcification times were monitored in order to
determine the eﬀect on blood clotting of the nanoparticle
suspensions. Fresh sheep’s blood (0.1 mL) was added directly
to a clotting tube at 37 1C, followed by either water, an aqueous
solution of heparin (5 mg ml1 in water), non-stabilised Fe3O4
nanoparticles (50 mg ml1 in water) or the as-prepared stable
colloidal suspensions of nanoparticles prepared according to
Table 1 (0.1 mL) and CaCl2 (0.1 mL, 0.025 M) and a stopwatch
started. The clotting tube was tilted at 30 s intervals until a firm
clot had formed. Samples tested in a magnetic field were
subjected to an identical procedure in the presence of a mag-
netic field (B0.1 T). The diﬀerences in the results obtained from
nanoparticles (non-stabilised and stabilised) and controls were
analysed statistically using the two-sample t-test (P o 0.05).
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